There is a steady stream of investigational antimalarials coming out of pre-clinical development. Their efficient and speedy early phase testing is required so that they can be deployed to treat drug-resistant malaria and achieve elimination. In this presentation, the use of volunteer infection studies with malaria to get pivotal clinical efficacy data will be described. Examples of the progress of drugs through this process will be given.